
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.

Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.

Andrea Necchi, MD, discusses response-adapted treatment, higher complete response rates, and the potential to reduce the need for cystectomy and additional adjuvant therapy in muscle-invasive bladder cancer.

At ESMO 2026, experts forecast how RAS inhibitors, new prostate cancer therapies, and IO combinations may reshape pancreatic, prostate, and endometrial care.

Morana Vojnic, MD, MBA, explains how FET-PET imaging's FDA approval is enabling neuro-oncologists to identify pseudoprogression and prolong effective treatments.

Necchi discusses the evolving role of ADC–immunotherapy combinations in muscle-invasive bladder cancer, chemotherapy after combination treatment, and the exception of tumors with small cell features.

Divarasib’s ORR was 58% vs 32% for sotorasib or adagrasib in the phase 3 Krascendo 1 trial. Dr Skoulidis discusses response, durability, and survival.

CT, mouse, and bronchoscopy data link higher body fat to increased lung cancer risk, implicating regulatory T cells as a prevention target.

Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.

Ferdinandos Skoulidis, MD, PhD, explores emerging KRAS-targeted therapies in KRAS-mutated non–small cell lung cancer.

Hans Lee, MD, and Natasha Edwin, MD, discuss how they prioritize making bispecific antibodies available in the community setting for multiple myeloma.

Merieme Klobocista, MD, explains how surgical history, disease burden, and body habits guide minimally invasive surgery decisions in gynecologic cancer.

Lauren Banks, MD, PhD, explains early findings from a pilot study of lifileucel in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma, including treatment feasibility, safety, and response durability.

Obesity and lung cancer research shows mixed results; experts urge moving beyond BMI to waist metrics and CT-based body composition for clearer risk insights.

Merieme Klobocista, MD, of Hackensack Meridian Health explains how molecular testing is personalizing treatment for ovarian and uterine cancer.

Sara Lonardi, MD, discusses the final overall survival analysis of CheckMate-8HW from ESMO 2026 and its implications for first-line MSI-H/dMMR mCRC.

Nikhil I. Khushalani, MD, discusses outcomes of the HBI-8000-303 trial of a new combination in frontline advanced melanoma.

Daniel Heng, MD, MPH, FRCPC, discusses LITESPARK-011 and LITESPARK-012 data defining belzutifan's role in second-line and later advanced RCC.

Georgina V. Long, AO, BSc, PhD, MBBS, discusses the effort that goes into producing intismeran autogene neoantigen therapy tailored to each patient.

In an interview, David J. Benjamin, MD, explains the findings on gender makeup of NCCN guideline panels he presented at the 2026 ESMO Congress.

Lauren Banks, MD, PhD, discusses early lifileucel responses, safety findings, and next steps in the phase 2 SARATOGA trial for advanced soft tissue sarcoma.

New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.

Zev A. Wainberg, MD, MSc, reviews RASolute 302 findings on daraxonrasib's OS benefit across RAS genotypes in metastatic pancreatic cancer.

Bhavana Pothuri, MD, discusses TroFuse-005 at ESMO 2026, including TROP2 expression, treatment sequencing, and the future of endometrial cancer care.

Lauren Banks, MD, PhD, discusses TIL therapy feasibility and safety in dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma.

Funda Meric-Bernstam, MD, discusses the outcomes of the FONTANA trial of an investigational folate receptor alpha–targeting antibody-drug conjugate in platinum-resistant ovarian cancer.

Bhavana Pothuri, MD, discusses phase 3 TroFuse-005 data from ESMO, where sac-TMT improved PFS and OS vs chemotherapy in endometrial cancer.

Domenica Lorusso, MD, PhD, discusses phase 3 findings on sacituzumab tirumotecan in advanced or recurrent endometrial cancer.

Brian M. Slomovitz, MD, discusses the outcomes of the KEYNOTE-C93 trial of pembrolizumab for endometrial cancer.

Tamim Niazi, MDCM, discusses key findings from the phase 3 DASL-HiCaP study presented at the 2026 ESMO Congress.

Dr Jacob Sands discusses first-look OS and PFS data for tarlatamab plus durvalumab maintenance from the phase 3 DeLLphi-305 trial at ESMO 2026.